カンナビジオール (Japanese Wikipedia)

DEA News Release, DEA Eases Requirements for FDA Approved Clinical Trials on Cannabidiol (December 23, 2015) ("CBD is a Schedule I controlled substance as defined under the CSA."), http://www.dea.gov/divisions/hq/2015/hq122315.shtml; Joseph T. Rannazzisi Deputy Assistant Administrator Drug Enforcement Administration Before the Caucus on International Narcotics Control, United States Senate, at 2 (June 24, 2015) (CBD is a Schedule I drug.); see also Frank Robison, Elvira Strehle-Henson, Cannabis Laws and Research at Colorado Institutions of Higher Education, COLO. LAW., OCTOBER 2015, AT 73, 76 ("[T]the DEA's position on CBD is clear—it is a Schedule I substance.").

doi.org (Global: 2^nd place; Japanese: 6^th place)

“Cannabidiol: an overview of some pharmacological aspects”. J Clin Pharmacol 42 (11 Suppl): 11S–19S. (November 2002). doi:10.1177/0091270002238789. PMID 12412831.
“Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders”. Phytother Res 23 (5): 597–602. (May 2009). doi:10.1002/ptr.2625. PMID 18844286.
^{[信頼性の低い医学の情報源？]} “Cannabis and cannabis extracts: greater than the sum of their parts?”. Journal of Cannabis Therapeutics 1 (3/4): 103–132. (2001). doi:10.1300/J175v01n03_08.
“The pharmacologic and clinical effects of medical cannabis”. Pharmacotherapy 33 (2): 195–209. (February 2013). doi:10.1002/phar.1187. PMID 23386598.
Aizpurua-Olaizola, Oier (February 2, 2016). “Evolution of the Cannabinoid and Terpene Content during the Growth ofCannabis sativaPlants from Different Chemotypes” (英語). Journal of Natural Products 79 (2): 324–331. doi:10.1021/acs.jnatprod.5b00949. PMID 26836472.
渡辺正仁、早崎華、由留木裕子、渡辺克哉「カンナビジオールの治療効果とその作用機序」『保健医療学雑誌』9巻（2号）、2018年、112–125頁。doi:10.15563/jalliedhealthsci.9.112。NAID 130007492289。
“Cannabinoids for epilepsy”. Cochrane Database Syst Rev 6 (6): CD009270. (June 13, 2012). doi:10.1002/14651858.CD009270.pub2. PMID 22696383.
Amy Maxmen. “大麻由来の抗てんかん薬が米国で承認”. Nature ダイジェスト. doi:10.1038/ndigest.2018.181015. 2021年1月17日閲覧。
Maa, Edward (2014). “The case for medical marijuana in epilepsy”. Epilepsia 55 (6): 783–786. doi:10.1111/epi.12610. ISSN 0013-9580.
“Therapeutic Potential of Cannabinoids in Psychosis”. Biol. Psychiatry 79 (7): 604–12. (2016). doi:10.1016/j.biopsych.2015.11.018. PMID 26852073.
Schubart CD et al (2013). “Cannabidiol as a potential treatment for psychosis”. European Neuropsychopharmacology 24 (1): 51–64. doi:10.1016/j.euroneuro.2013.11.002. PMID 24309088.
McGuire, Philip; Robson, Philip; Cubala, Wieslaw Jerzy; et al. (2017年). “Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial”. American Journal of Psychiatry: appi.ajp.2017.1. doi:10.1176/appi.ajp.2017.17030325. PMID 29241357.
Bergamaschi, Mateus M; Queiroz, Regina Helena Costa; Chagas, Marcos Hortes Nisihara; et al. (2011年). “Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients”. Neuropsychopharmacology. 36 (6): 1219–1226. doi:10.1038/npp.2011.6. PMC 3079847. PMID 21307846.
Palmieri B, Laurino C, Vadalà M (2019). “A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars”. Clin Ter 170 (2): e93–e99. doi:10.7417/CT.2019.2116. PMID 30993303.
Devinsky O (Jun 2014). “Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders”. Epilepsia 55 (6): 791–802. doi:10.1111/epi.12631. PMC 4707667. PMID 24854329.
“Cannabidiol—recent advances”. Chem. Biodivers. 4 (8): 1678–92. (August 2007). doi:10.1002/cbdv.200790147. PMID 17712814.
Pertwee RG (2008). “The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin”. British Journal of Pharmacology 153 (2): 199–215. doi:10.1038/sj.bjp.0707442. PMC 2219532. PMID 17828291.
“Cannabidiol potentiates pharmacological effects of Δ9-tetrahydrocannabinol via CB1 receptor-dependent mechanism”. Brain Research 1188: 157–164. (2008). doi:10.1016/j.brainres.2007.09.090. PMID 18021759.
“The orphan receptor GPR55 is a novel cannabinoid receptor”. British Journal of Pharmacology 152 (7): 1092–101. (2007). doi:10.1038/sj.bjp.0707460. PMC 2095107. PMID 17876302.
Russo, Ethan B.; Burnett, Andrea; Hall, Brian; et al. (2005年). “Agonistic Properties of Cannabidiol at 5-HT1a Receptors”. Neurochemical Research. 30 (8): 1037–1043. doi:10.1007/s11064-005-6978-1. PMID 16258853.
“Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors”. British Journal of Pharmacology 159 (1): 122–8. (January 2010). doi:10.1111/j.1476-5381.2009.00521.x. PMC 2823358. PMID 20002102.
“5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats”. British Journal of Pharmacology 156 (1): 181–8. (January 2009). doi:10.1111/j.1476-5381.2008.00046.x. PMC 2697769. PMID 19133999.
“Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats”. Psychopharmacology 199 (2): 223–30. (August 2008). doi:10.1007/s00213-008-1168-x. PMID 18446323.
“Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism”. Stroke; a Journal of Cerebral Circulation 36 (5): 1077–82. (May 2005). doi:10.1161/01.STR.0000163083.59201.34. PMID 15845890.
“Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance”. Neuropharmacology 52 (4): 1079–87. (March 2007). doi:10.1016/j.neuropharm.2006.11.005. PMID 17320118.
“Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors”. Naunyn-Schmiedeberg's Archives of Pharmacology 372 (5): 354–361. (2006). doi:10.1007/s00210-006-0033-x. PMID 16489449.
“Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders”. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 367 (1607): 3364–78. (December 2012). doi:10.1098/rstb.2011.0389. PMC 3481531. PMID 23108553.
“Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy”. Cannabis and Cannabinoid Research 1 (1): 90–101. (2014). doi:10.1089/can.2015.0012.
“Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats”. Psychopharmacology 218 (2): 443–457. (November 2011). doi:10.1007/s00213-011-2342-0. PMID 21667074.
“Evidence that Cannabidiol Does Not Significantly Alter the Pharmacokinetics of Tetrahydrocannabinol in Man”. Journal of Pharmacokinetics and Biopharmaceutics 9 (3): 245–260. (June 1981). doi:10.1007/BF01059266. PMID 6270295.
Gaston, Tyler E.; Bebin, E. Martina; Cutter, Gary R.; et al. (2017年). “Interactions between cannabidiol and commonly used antiepileptic drugs”. Epilepsia. 58 (9): 1586–1592. doi:10.1111/epi.13852. PMID 28782097.
“Cannabidiol”. Acta Crystallogr. B 33 (10): 3211–3214. (1977). doi:10.1107/S0567740877010577.
“Hashish—XIII On the nature of the beam test”. Tetrahedron 24 (16): 5615–5624. (1968). doi:10.1016/0040-4020(68)88159-1. PMID 5732891.
“Synthese und Chiralität des (−)-Cannabidiols”. Helv. Chim. Acta 50 (2): 719–723. (1967). doi:10.1002/hlca.19670500235. PMID 5587099.
“Boron trifluoride etherate on alumuna — a modified Lewis acid reagent. An improved synthesis of cannabidiol”. Tetrahedron Letters 26 (8): 1083–1086. (1985). doi:10.1016/S0040-4039(00)98518-6.
“Synthesis of cannabidiols via alkenylation of cyclohexenyl monoacetate”. Org. Lett. 8 (13): 2699–2702. (2006). doi:10.1021/ol060692h. PMID 16774235.
“Identification of candidate genes affecting Δ9-tetrahydrocannabinol biosynthesis in Cannabis sativa”. Journal of Experimental Botany 60 (13): 3715–3726. (2009). doi:10.1093/jxb/erp210. PMC 2736886. PMID 19581347.
Taura, F., Sirikantaramas, S., Shoyama, Y., Yoshikai, K., Shoyama, Y., Morimoto, S. (2007). “Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa”. FEBS Letters 581 (16): 2929–34. doi:10.1016/j.febslet.2007.05.043. PMID 17544411.
Sachs J et al (Oct 2015). “Safety and Toxicology of Cannabinoids”. Neurotherapeutics 12 (4): 735–746. doi:10.1007/s13311-015-0380-8. PMC 4604177. PMID 26269228.
“A systematic review of the antipsychotic properties of cannabidiol in humans”. Schizophr. Res. 162 (1–3): 153–61. (2015). doi:10.1016/j.schres.2015.01.033. PMID 25667194.
“Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb”. Trends Pharmacol. Sci. 30 (10): 515–27. (2009). doi:10.1016/j.tips.2009.07.006. PMID 19729208.
“Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb”. Trends Pharmacol. Sci. 30 (10): 515–27. (2009). doi:10.1016/j.tips.2009.07.006. PMID 19729208.
Scali, Monica; Dufresnes, Christophe; Jan, Catherine; et al. (2017年). “Broad-Scale Genetic Diversity of Cannabis for Forensic Applications”. PLOS ONE. 12 (1): e0170522. doi:10.1371/journal.pone.0170522. PMC 5249207. PMID 28107530.{{cite journal2}}: CS1メンテナンス: ページ番号として指定されている記事番号 (カテゴリ) CS1メンテナンス: 明示されていないフリーアクセスDOI (カテゴリ)
Fournier, G. (2003). “Intérêt du rapport Δ-9-THC / CBD dans le contrôle des cultures de chanvre industriel”. Annales de Toxicologie Analytique 15 (4): 250–259. doi:10.1051/ata/2003003.

doseofnature.com (Global: low place; Japanese: low place)

“Marijuana stops child's severe seizures”. CNN. 2016年1月7日閲覧。

dravetfoundation.org (Global: low place; Japanese: low place)

“What is Dravet Syndrome?”. Dravetfoundation.org (2014年6月20日). 2016年12月4日閲覧。

eiha.org (Global: low place; Japanese: low place)

“Support the EIHA CBD position paper - EIHA European Industrial Hemp Association”. 2018年9月23日閲覧。

epilepsyresearch.org.uk (Global: low place; Japanese: low place)

“Cannabis-Derived Dravet Syndrome Drug Gets US Orphan Drug Approval” (2013年11月18日). 2015年7月21日閲覧。

europa.eu (Global: 68^th place; Japanese: 425^th place)

ec.europa.eu

“CosIng – Cosmetics – GROWTH – European Commission”. Ec.europa.eu. 2016年12月4日閲覧。

fda.gov (Global: 447^th place; Japanese: 1,043^rd place)

“Cannabidiol: Barriers to Research and Potential Medical Benefits”. FDA (2015年6月24日). 2015年12月15日閲覧。

fsai.ie (Global: low place; Japanese: low place)

“CBD Oils and Hemp Oils - Legal Status”. 2018年9月23日閲覧。

globenewswire.com (Global: 2,614^th place; Japanese: 6,858^th place)

“GW Pharmaceuticals Receives Orphan Drug Designation from the European Medicines Agency (EMA) for Cannabidiol for the Treatment of Tuberous Sclerosis” (Press release). Nasdaq. 27 February 2018. 2018年3月25日閲覧.

gov.uk (Global: 432^nd place; Japanese: 1,191^st place)

“MHRA statement on products containing Cannabidiol (CBD)”. Gov.uk. (2016年12月14日)

greenzonejapan.wordpress.com (Global: low place; Japanese: low place)

“Project CBD 主催者マーチン・リーに訊く”. GREEN ZONE JAPAN (2018年2月14日). 2018年3月1日閲覧。

hc-sc.gc.ca (Global: low place; Japanese: low place)

“Fact Sheet — Sativex”. Health Canada. 2013年5月16日閲覧。

justice.gc.ca (Global: 2,540^th place; Japanese: low place)

laws-lois.justice.gc.ca

“Controlled Drugs and Substances Act – Schedule II”. Laws-lois.justice.gc.ca. 2016年12月4日閲覧。

kenkyuukai.jp (Global: low place; Japanese: 9,745^th place)

cannabis.kenkyuukai.jp

World Health Organization、日本臨床カンナビノイド学会『カンナビジオール（CBD）事前審査報告書 (pdf)』（レポート）、世界保健機関、2017年12月6日。2017年12月5日閲覧。 [1] World Health Organization (2017年12月6日). CANNABIDIOL Pre-Review Report Agenda Item 5.2 : Expert Committee on Drug Dependence Thirty-ninth Meeting (pdf) (Report). 世界保健機関. 2017年12月5日閲覧.
テドロス・アダノム・ゲブレシウス、 (23 July 2018). 国連事務総長（アントニオ・グテーレス氏）への手紙 (pdf) (Report). Translated by 日本臨床カンナビノイド学会. 世界保健機関. 2019年1月15日閲覧.{{cite report}}: CS1メンテナンス: 複数の名前/author (カテゴリ) 原文：ECDD 40th meetingのDirector-General letter 。翻訳文書の経緯：“2018年6月第40回WHO ECDD会議の結果について”. 日本臨床カンナビノイド学会 (2018年9月3日). 2019年1月15日閲覧。
“欧州連合司法裁判所の20年11月19日判決「CBDは麻薬ではない」”. 日本臨床カンナビノイド学会 (2021年1月26日). 2021年1月28日閲覧。

kentucky.com (Global: 3,350^th place; Japanese: low place)

“Hemp industry is growing in Kentucky, attracting processors, investment | Lexington Herald-Leader”. Kentucky.com (2015年5月5日). 2016年12月4日閲覧。

latimes.com (Global: 22^nd place; Japanese: 197^th place)

articles.latimes.com

“On the frontier of medical pot to treat boy's epilepsy”. (2012年9月13日)

legislation.gov.au (Global: 6,658^th place; Japanese: low place)

“Poisons Standard March 2016”. Legislation.gov.au. 2016年12月4日閲覧。

m3.com (Global: low place; Japanese: 2,027^th place)

“カンナビジオール医薬品の早期承認を要望日本てんかん学会”. m3.com (2019年9月23日). 2021年1月17日閲覧。

medicaldaily.com (Global: low place; Japanese: low place)

“Marijuana's Main Ingredient, Cannabidiol, May Be An Effective Way To Treat Epilepsy”. Medical Daily. (2015年12月8日) 2015年12月14日閲覧。

medicines.org.uk (Global: 3,823^rd place; Japanese: low place)

“Sativex Oromucosal Spray – Summary of Product Characteristics (SPC) – (eMC)”. Medicines.org.uk. 2016年12月4日閲覧。

medscape.com (Global: 719^th place; Japanese: 3,311^th place)

Melville, Nancy A. (August 14, 2013), Seizure Disorders Enter Medical Marijuana Debate, Medscape Medical News. 2014年1月14日閲覧。

mhlw.go.jp (Global: 1,656^th place; Japanese: 110^th place)

ncd.mhlw.go.jp

関東信越厚生局麻薬取締部 (2020年5月). “CBD製品の大麻非該当性の確認について”. 麻薬取締部ウェブサイト. 2021年1月17日閲覧。手続きに関する付属のPDFも参照。

mhlw.go.jp

“大麻取締法等の一部を改正する法律について”. 厚生労働省. 2025年10月30日閲覧。

nature.com (Global: 234^th place; Japanese: 363^rd place)

Bergamaschi, Mateus M; Queiroz, Regina Helena Costa; Chagas, Marcos Hortes Nisihara; et al. (2011年). “Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients”. Neuropsychopharmacology. 36 (6): 1219–1226. doi:10.1038/npp.2011.6. PMC 3079847. PMID 21307846.

natureasia.com (Global: low place; Japanese: 2,077^th place)

Amy Maxmen. “大麻由来の抗てんかん薬が米国で承認”. Nature ダイジェスト. doi:10.1038/ndigest.2018.181015. 2021年1月17日閲覧。

ncsl.org (Global: 6,017^th place; Japanese: low place)

State Industrial Hemp Statutes.

newsweek.com (Global: 269^th place; Japanese: 994^th place)

“The Great Kentucky Hemp Experiment”. Newsweek.com (2015年10月23日). 2016年12月4日閲覧。

nih.gov (Global: 4^th place; Japanese: 24^th place)

pubmed.ncbi.nlm.nih.gov

“Cannabidiol: an overview of some pharmacological aspects”. J Clin Pharmacol 42 (11 Suppl): 11S–19S. (November 2002). doi:10.1177/0091270002238789. PMID 12412831.
“Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders”. Phytother Res 23 (5): 597–602. (May 2009). doi:10.1002/ptr.2625. PMID 18844286.
“The pharmacologic and clinical effects of medical cannabis”. Pharmacotherapy 33 (2): 195–209. (February 2013). doi:10.1002/phar.1187. PMID 23386598.
Aizpurua-Olaizola, Oier (February 2, 2016). “Evolution of the Cannabinoid and Terpene Content during the Growth ofCannabis sativaPlants from Different Chemotypes” (英語). Journal of Natural Products 79 (2): 324–331. doi:10.1021/acs.jnatprod.5b00949. PMID 26836472.
“Cannabinoids for epilepsy”. Cochrane Database Syst Rev 6 (6): CD009270. (June 13, 2012). doi:10.1002/14651858.CD009270.pub2. PMID 22696383.
“Therapeutic Potential of Cannabinoids in Psychosis”. Biol. Psychiatry 79 (7): 604–12. (2016). doi:10.1016/j.biopsych.2015.11.018. PMID 26852073.
Schubart CD et al (2013). “Cannabidiol as a potential treatment for psychosis”. European Neuropsychopharmacology 24 (1): 51–64. doi:10.1016/j.euroneuro.2013.11.002. PMID 24309088.
McGuire, Philip; Robson, Philip; Cubala, Wieslaw Jerzy; et al. (2017年). “Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial”. American Journal of Psychiatry: appi.ajp.2017.1. doi:10.1176/appi.ajp.2017.17030325. PMID 29241357.
Bergamaschi, Mateus M; Queiroz, Regina Helena Costa; Chagas, Marcos Hortes Nisihara; et al. (2011年). “Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients”. Neuropsychopharmacology. 36 (6): 1219–1226. doi:10.1038/npp.2011.6. PMC 3079847. PMID 21307846.
Palmieri B, Laurino C, Vadalà M (2019). “A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars”. Clin Ter 170 (2): e93–e99. doi:10.7417/CT.2019.2116. PMID 30993303.
Devinsky O (Jun 2014). “Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders”. Epilepsia 55 (6): 791–802. doi:10.1111/epi.12631. PMC 4707667. PMID 24854329.
“Cannabidiol—recent advances”. Chem. Biodivers. 4 (8): 1678–92. (August 2007). doi:10.1002/cbdv.200790147. PMID 17712814.
Pertwee RG (2008). “The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin”. British Journal of Pharmacology 153 (2): 199–215. doi:10.1038/sj.bjp.0707442. PMC 2219532. PMID 17828291.
“Cannabidiol potentiates pharmacological effects of Δ9-tetrahydrocannabinol via CB1 receptor-dependent mechanism”. Brain Research 1188: 157–164. (2008). doi:10.1016/j.brainres.2007.09.090. PMID 18021759.
“The orphan receptor GPR55 is a novel cannabinoid receptor”. British Journal of Pharmacology 152 (7): 1092–101. (2007). doi:10.1038/sj.bjp.0707460. PMC 2095107. PMID 17876302.
Russo, Ethan B.; Burnett, Andrea; Hall, Brian; et al. (2005年). “Agonistic Properties of Cannabidiol at 5-HT1a Receptors”. Neurochemical Research. 30 (8): 1037–1043. doi:10.1007/s11064-005-6978-1. PMID 16258853.
“Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors”. British Journal of Pharmacology 159 (1): 122–8. (January 2010). doi:10.1111/j.1476-5381.2009.00521.x. PMC 2823358. PMID 20002102.
“5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats”. British Journal of Pharmacology 156 (1): 181–8. (January 2009). doi:10.1111/j.1476-5381.2008.00046.x. PMC 2697769. PMID 19133999.
“Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats”. Psychopharmacology 199 (2): 223–30. (August 2008). doi:10.1007/s00213-008-1168-x. PMID 18446323.
“Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism”. Stroke; a Journal of Cerebral Circulation 36 (5): 1077–82. (May 2005). doi:10.1161/01.STR.0000163083.59201.34. PMID 15845890.
“Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance”. Neuropharmacology 52 (4): 1079–87. (March 2007). doi:10.1016/j.neuropharm.2006.11.005. PMID 17320118.
“Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors”. Naunyn-Schmiedeberg's Archives of Pharmacology 372 (5): 354–361. (2006). doi:10.1007/s00210-006-0033-x. PMID 16489449.
“Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders”. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 367 (1607): 3364–78. (December 2012). doi:10.1098/rstb.2011.0389. PMC 3481531. PMID 23108553.
“Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain”. Drug Metabolism and Disposition 23 (8): 825–831. (August 1995). PMID 7493549.
“Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats”. Psychopharmacology 218 (2): 443–457. (November 2011). doi:10.1007/s00213-011-2342-0. PMID 21667074.
“Evidence that Cannabidiol Does Not Significantly Alter the Pharmacokinetics of Tetrahydrocannabinol in Man”. Journal of Pharmacokinetics and Biopharmaceutics 9 (3): 245–260. (June 1981). doi:10.1007/BF01059266. PMID 6270295.
Gaston, Tyler E.; Bebin, E. Martina; Cutter, Gary R.; et al. (2017年). “Interactions between cannabidiol and commonly used antiepileptic drugs”. Epilepsia. 58 (9): 1586–1592. doi:10.1111/epi.13852. PMID 28782097.
“Hashish—XIII On the nature of the beam test”. Tetrahedron 24 (16): 5615–5624. (1968). doi:10.1016/0040-4020(68)88159-1. PMID 5732891.
“Synthese und Chiralität des (−)-Cannabidiols”. Helv. Chim. Acta 50 (2): 719–723. (1967). doi:10.1002/hlca.19670500235. PMID 5587099.
“Synthesis of cannabidiols via alkenylation of cyclohexenyl monoacetate”. Org. Lett. 8 (13): 2699–2702. (2006). doi:10.1021/ol060692h. PMID 16774235.
“Identification of candidate genes affecting Δ9-tetrahydrocannabinol biosynthesis in Cannabis sativa”. Journal of Experimental Botany 60 (13): 3715–3726. (2009). doi:10.1093/jxb/erp210. PMC 2736886. PMID 19581347.
Taura, F., Sirikantaramas, S., Shoyama, Y., Yoshikai, K., Shoyama, Y., Morimoto, S. (2007). “Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa”. FEBS Letters 581 (16): 2929–34. doi:10.1016/j.febslet.2007.05.043. PMID 17544411.
Sachs J et al (Oct 2015). “Safety and Toxicology of Cannabinoids”. Neurotherapeutics 12 (4): 735–746. doi:10.1007/s13311-015-0380-8. PMC 4604177. PMID 26269228.
“A systematic review of the antipsychotic properties of cannabidiol in humans”. Schizophr. Res. 162 (1–3): 153–61. (2015). doi:10.1016/j.schres.2015.01.033. PMID 25667194.
“Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb”. Trends Pharmacol. Sci. 30 (10): 515–27. (2009). doi:10.1016/j.tips.2009.07.006. PMID 19729208.
“Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb”. Trends Pharmacol. Sci. 30 (10): 515–27. (2009). doi:10.1016/j.tips.2009.07.006. PMID 19729208.
Scali, Monica; Dufresnes, Christophe; Jan, Catherine; et al. (2017年). “Broad-Scale Genetic Diversity of Cannabis for Forensic Applications”. PLOS ONE. 12 (1): e0170522. doi:10.1371/journal.pone.0170522. PMC 5249207. PMID 28107530.{{cite journal2}}: CS1メンテナンス: ページ番号として指定されている記事番号 (カテゴリ) CS1メンテナンス: 明示されていないフリーアクセスDOI (カテゴリ)

pmc.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

Bergamaschi, Mateus M; Queiroz, Regina Helena Costa; Chagas, Marcos Hortes Nisihara; et al. (2011年). “Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients”. Neuropsychopharmacology. 36 (6): 1219–1226. doi:10.1038/npp.2011.6. PMC 3079847. PMID 21307846.
Scali, Monica; Dufresnes, Christophe; Jan, Catherine; et al. (2017年). “Broad-Scale Genetic Diversity of Cannabis for Forensic Applications”. PLOS ONE. 12 (1): e0170522. doi:10.1371/journal.pone.0170522. PMC 5249207. PMID 28107530.{{cite journal2}}: CS1メンテナンス: ページ番号として指定されている記事番号 (カテゴリ) CS1メンテナンス: 明示されていないフリーアクセスDOI (カテゴリ)

nii.ac.jp (Global: 304^th place; Japanese: 20^th place)

ci.nii.ac.jp

渡辺正仁、早崎華、由留木裕子、渡辺克哉「カンナビジオールの治療効果とその作用機序」『保健医療学雑誌』9巻（2号）、2018年、112–125頁。doi:10.15563/jalliedhealthsci.9.112。NAID 130007492289。

nytimes.com (Global: 7^th place; Japanese: 63^rd place)

Shear, Michael D. (February 7, 2014) In Signing Farm Bill, Obama Extols Rural Growth.

pharmtech.com (Global: low place; Japanese: low place)

“EMA Grants Orphan Drug Designation to Epidiolex for Treatment of Lennox-Gastaut Syndrome”. Pharmatech 2017年9月15日閲覧。

plos.org (Global: 2,112^th place; Japanese: 1,782^nd place)

journals.plos.org

Scali, Monica; Dufresnes, Christophe; Jan, Catherine; et al. (2017年). “Broad-Scale Genetic Diversity of Cannabis for Forensic Applications”. PLOS ONE. 12 (1): e0170522. doi:10.1371/journal.pone.0170522. PMC 5249207. PMID 28107530.{{cite journal2}}: CS1メンテナンス: ページ番号として指定されている記事番号 (カテゴリ) CS1メンテナンス: 明示されていないフリーアクセスDOI (カテゴリ)

researchgate.net (Global: 120^th place; Japanese: 616^th place)

“Therapeutic Potential of Cannabinoids in Psychosis”. Biol. Psychiatry 79 (7): 604–12. (2016). doi:10.1016/j.biopsych.2015.11.018. PMID 26852073.

telegraph.co.uk (Global: 30^th place; Japanese: 177^th place)

“Growing marijuana that won't get you high”. London. (2010年10月26日)

thch-vape.shop (Global: low place; Japanese: low place)

“2024年12月の大麻取締法改正で何が変わったのか”. THCH Vape Shop. 2025年10月30日閲覧。

tjapan.jp (Global: low place; Japanese: 5,274^th place)

Naho Sasaki (2019年4月2日). “コスメティックは未来を変えられるか？Vol.2 現代人の救世主「CBDオイル」”. T JAPAN:The New York Times Style Magazine. 2021年1月28日閲覧。

uocc.co.jp (Global: low place; Japanese: low place)

oem.uocc.co.jp

CBDのOEMメーカー

uspto.gov (Global: 1,459^th place; Japanese: 2,442^nd place)

patft.uspto.gov

wa.gov (Global: 2,121^st place; Japanese: low place)

lawfilesext.leg.wa.gov

HOUSE BILL REPORT SSB 5012. leg.wa.gov

who.int (Global: 195^th place; Japanese: 376^th place)

“International Nonproprietary Names for Pharmaceutical Substances (INN)”. WHO Drug Information 30 (2): 241. (2016).
World Health Organization、日本臨床カンナビノイド学会『カンナビジオール（CBD）事前審査報告書 (pdf)』（レポート）、世界保健機関、2017年12月6日。2017年12月5日閲覧。 [1] World Health Organization (2017年12月6日). CANNABIDIOL Pre-Review Report Agenda Item 5.2 : Expert Committee on Drug Dependence Thirty-ninth Meeting (pdf) (Report). 世界保健機関. 2017年12月5日閲覧.
テドロス・アダノム・ゲブレシウス、 (23 July 2018). 国連事務総長（アントニオ・グテーレス氏）への手紙 (pdf) (Report). Translated by 日本臨床カンナビノイド学会. 世界保健機関. 2019年1月15日閲覧.{{cite report}}: CS1メンテナンス: 複数の名前/author (カテゴリ) 原文：ECDD 40th meetingのDirector-General letter 。翻訳文書の経緯：“2018年6月第40回WHO ECDD会議の結果について”. 日本臨床カンナビノイド学会 (2018年9月3日). 2019年1月15日閲覧。

worldcat.org (Global: 5^th place; Japanese: 19^th place)

search.worldcat.org

Maa, Edward (2014). “The case for medical marijuana in epilepsy”. Epilepsia 55 (6): 783–786. doi:10.1111/epi.12610. ISSN 0013-9580.

カンナビジオール (Japanese Wikipedia)

advancedholistichealth.org (Global: low place; Japanese: low place)

aesnet.org (Global: low place; Japanese: low place)

ajc.com (Global: 685th place; Japanese: 3,482nd place)

alchimiaweb.com (Global: low place; Japanese: low place)

ama-assn.org (Global: 3,257th place; Japanese: 6,629th place)

asahi.com (Global: 141st place; Japanese: 9th place)

bloodyelbow.com (Global: 1,297th place; Japanese: 1,833rd place)

bloomberg.co.jp (Global: 4,571st place; Japanese: 282nd place)

canada.ca (Global: 1,712th place; Japanese: 7,476th place)

cannabis-med.org (Global: low place; Japanese: low place)

colorado.gov (Global: 5,761st place; Japanese: low place)

dea.gov (Global: 8,191st place; Japanese: low place)

doi.org (Global: 2nd place; Japanese: 6th place)

doseofnature.com (Global: low place; Japanese: low place)

dravetfoundation.org (Global: low place; Japanese: low place)

eiha.org (Global: low place; Japanese: low place)

epilepsyresearch.org.uk (Global: low place; Japanese: low place)

europa.eu (Global: 68th place; Japanese: 425th place)

ec.europa.eu

fda.gov (Global: 447th place; Japanese: 1,043rd place)

fsai.ie (Global: low place; Japanese: low place)

globenewswire.com (Global: 2,614th place; Japanese: 6,858th place)

gov.uk (Global: 432nd place; Japanese: 1,191st place)

greenzonejapan.wordpress.com (Global: low place; Japanese: low place)

hc-sc.gc.ca (Global: low place; Japanese: low place)

justice.gc.ca (Global: 2,540th place; Japanese: low place)

laws-lois.justice.gc.ca

kenkyuukai.jp (Global: low place; Japanese: 9,745th place)

cannabis.kenkyuukai.jp

kentucky.com (Global: 3,350th place; Japanese: low place)

latimes.com (Global: 22nd place; Japanese: 197th place)

articles.latimes.com

legislation.gov.au (Global: 6,658th place; Japanese: low place)

m3.com (Global: low place; Japanese: 2,027th place)

medicaldaily.com (Global: low place; Japanese: low place)

medicines.org.uk (Global: 3,823rd place; Japanese: low place)

medscape.com (Global: 719th place; Japanese: 3,311th place)

mhlw.go.jp (Global: 1,656th place; Japanese: 110th place)

ncd.mhlw.go.jp

mhlw.go.jp

nature.com (Global: 234th place; Japanese: 363rd place)

natureasia.com (Global: low place; Japanese: 2,077th place)

ncsl.org (Global: 6,017th place; Japanese: low place)

newsweek.com (Global: 269th place; Japanese: 994th place)

nih.gov (Global: 4th place; Japanese: 24th place)

pubmed.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

nii.ac.jp (Global: 304th place; Japanese: 20th place)

ci.nii.ac.jp

nytimes.com (Global: 7th place; Japanese: 63rd place)

pharmtech.com (Global: low place; Japanese: low place)

plos.org (Global: 2,112th place; Japanese: 1,782nd place)

journals.plos.org

researchgate.net (Global: 120th place; Japanese: 616th place)

telegraph.co.uk (Global: 30th place; Japanese: 177th place)

thch-vape.shop (Global: low place; Japanese: low place)

tjapan.jp (Global: low place; Japanese: 5,274th place)

uocc.co.jp (Global: low place; Japanese: low place)

oem.uocc.co.jp

uspto.gov (Global: 1,459th place; Japanese: 2,442nd place)

patft.uspto.gov

wa.gov (Global: 2,121st place; Japanese: low place)

lawfilesext.leg.wa.gov

who.int (Global: 195th place; Japanese: 376th place)

worldcat.org (Global: 5th place; Japanese: 19th place)

search.worldcat.org

ajc.com (Global: 685^th place; Japanese: 3,482^nd place)

ama-assn.org (Global: 3,257^th place; Japanese: 6,629^th place)

asahi.com (Global: 141^st place; Japanese: 9^th place)

bloodyelbow.com (Global: 1,297^th place; Japanese: 1,833^rd place)

bloomberg.co.jp (Global: 4,571^st place; Japanese: 282^nd place)

canada.ca (Global: 1,712^th place; Japanese: 7,476^th place)

colorado.gov (Global: 5,761^st place; Japanese: low place)

dea.gov (Global: 8,191^st place; Japanese: low place)

doi.org (Global: 2^nd place; Japanese: 6^th place)

europa.eu (Global: 68^th place; Japanese: 425^th place)

fda.gov (Global: 447^th place; Japanese: 1,043^rd place)

globenewswire.com (Global: 2,614^th place; Japanese: 6,858^th place)

gov.uk (Global: 432^nd place; Japanese: 1,191^st place)

justice.gc.ca (Global: 2,540^th place; Japanese: low place)

kenkyuukai.jp (Global: low place; Japanese: 9,745^th place)

kentucky.com (Global: 3,350^th place; Japanese: low place)

latimes.com (Global: 22^nd place; Japanese: 197^th place)

legislation.gov.au (Global: 6,658^th place; Japanese: low place)

m3.com (Global: low place; Japanese: 2,027^th place)

medicines.org.uk (Global: 3,823^rd place; Japanese: low place)

medscape.com (Global: 719^th place; Japanese: 3,311^th place)

mhlw.go.jp (Global: 1,656^th place; Japanese: 110^th place)

nature.com (Global: 234^th place; Japanese: 363^rd place)

natureasia.com (Global: low place; Japanese: 2,077^th place)

ncsl.org (Global: 6,017^th place; Japanese: low place)

newsweek.com (Global: 269^th place; Japanese: 994^th place)

nih.gov (Global: 4^th place; Japanese: 24^th place)

nii.ac.jp (Global: 304^th place; Japanese: 20^th place)

nytimes.com (Global: 7^th place; Japanese: 63^rd place)

plos.org (Global: 2,112^th place; Japanese: 1,782^nd place)

researchgate.net (Global: 120^th place; Japanese: 616^th place)

telegraph.co.uk (Global: 30^th place; Japanese: 177^th place)

tjapan.jp (Global: low place; Japanese: 5,274^th place)

uspto.gov (Global: 1,459^th place; Japanese: 2,442^nd place)

wa.gov (Global: 2,121^st place; Japanese: low place)

who.int (Global: 195^th place; Japanese: 376^th place)

worldcat.org (Global: 5^th place; Japanese: 19^th place)